Agreements and Contracts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Agreements and Contracts

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 2

The latest pacts from the pharmaceutical supply chain.

Princeton, NJ (Feb. 6) Laureate Pharma, Inc. ( http://www.laureatepharma.com/) formed a partnership with Boehringer Ingelheim (Ingelheim, Germany, http://www.boehringer-ingelheim.com/). The partnership gives Laureate's clients access to Boehringer's manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture. Clients also will have access to large-scale commercial production by Boehringer at its facility in Biberach, Germany.

Keele, UK (Feb. 1)-Cobra Biomanufacturing Plc ( http://www.cobrabio.com/) formed an agreement with Pharmexa (HØrsholm, Denmark, http://www.pharmexa.com/) for the manufacture of "PX107" protein vaccine for use in Phase I clinical trials for bone disorders. Cobra will manufacture the protein, and Pharmexa will carry out upstream and downstream development of the vaccine.

Gaithersburg, MD (Feb. 1)- GenVec, Inc. ( http://www.genvec.com/) signed a three-year contract with the Department of Homeland Security (DHS, Washington, DC, http://www.dhs.gov/) to develop and manufacture vaccines against foot and mouth disease. GenVec will receive as much as $6 million in program funding the first year and as much as $15 million over three years if DHS exercises its annual renewal options under the contract. GenVec will be responsible for the development, production, and regulatory approval of the vaccine, while DHS will conduct animal studies.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here